Vagus nerve stimulation (VNS) for depression: What do we know now and what should be done next?

Current Psychiatry Reports

Volumn 8, Issue 6, 2006, Pages 445-451

  Nahas, Ziad ^a   Burns, Carol ^b   Foust, Milton J ^b   Short, Baron ^b   Herbsman, Tal ^b   George, Mark S ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

BIPOLAR DEPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DEPRESSION; DISEASE MODEL; DISEASE RESISTANCE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR DEPRESSION; NONHUMAN; PRACTICE GUIDELINE; PSYCHOTHERAPY; REVIEW; VAGUS NERVE STIMULATION;

BIPOLAR DISORDER; CHRONIC DISEASE; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; HUMANS; RECURRENCE; VAGUS NERVE;

EID: 33845890815     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0049-4     Document Type: Review

References (52)

1. Hirschfeld RM: American health care systems and depression: the past, present, and the future. J Clin Psychiatry 1998, 59(Suppl 20):5-10.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
3. Nestler EJ, Gould E, Manji H, et al.: Preclinical models: status of basic research in depression. Biol Psychiatry 2002, 52:503-528.
4. Kupfer DJ, Charney DS: Difficult-to-treat depression. Biol Psychiatry 2003, 53:633-634.
5. Nierenberg AA, Fava M, Trivedi MH, et al.: A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006, 163:1519-1530; quiz 1665.
6. McGrath PJ, Stewart JW, Fava M, et al.: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006, 163:1531-1541; quiz 1666.
7. Fava M, Rush AJ, Wisniewski SR, et al.: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006, 163:1161-1172.
8. Thase ME: Relapse and recurrence in unipolar major depression: short-term and long-term approaches. J Clin Psychiatry 1990, 51(Suppl):51-57.
9. Frank E, Rush AJ, Blehar M, et al.: Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders. Biol Psychiatry 2002, 52:631-654.
10. Frank E, Kupfer DJ, Perel JM, et al.: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990, 47:1093-1099.
11. Cosgrove GR, Rauch SL: Psychosurgery. Neurosurg Clin N Am 1995, 6:167-176.
12. Keller MB, Boland RJ: Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998, 44:348-360.
13. Schatzberg AF, Orsulak PJ, Rosenbaum AH, et al.: Toward a biochemical classification of depressive disorders, V: heterogeneity of unipolar depressions. Am J Psychiatry 1982, 139:471-475.
14. Blier P, de Montigny C: Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999, 21(Suppl 2):91S-98S.
15. Nemeroff CB, Owens MJ: Treatment of mood disorders. Nat Neurosci 2002, 5(Suppl):1068-1070.
16. Gutman DA, Owens MJ, Skelton KH, et al.: The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 2003, 304:874-880.
17. Sanacora G, Mason GF, Rothman DL, et al.: Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999, 56:1043-1047.
18. Paul IA, Nowak G, Layer RT, et al.: Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994, 269:95-102.
19. Shirayama Y, Chen AC, Nakagawa S, et al.: Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
20. Elger G, Hoppe C, Falkai P, et al.: Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 2000, 42:203-210.
21. Harden CL, Pulver MC, Ravdin LD, et al.: A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 2000, 1:93-99.
22. George MS, Sackeim HA, Marangell LB, et al.: Vagus nerve stimulation. A potential therapy for resistant depression? Psychiatr Clin North Am 2000, 23:757-783.
23. Post RM: Sensitization and kindling perspectives for the course of affective illness: toward a new treatment with the anticonvulsant carbamazepine. Pharmacopsychiatry 1990, 23:3-17.
24. Henry TR, Bakay RA, Votaw JR, et al.: Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia 1998, 39:983-990.
25. Krahl SE, Clark KB, Smith DC, Browning RA: Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998, 39:709-714.
26. Foley JO, DuBois F: Quantitative studies of the vagus nerve in the cat. I. The ratio of sensory and motor studies. J Comp Neurol 1937, 67:49-67.
27. Hallowitz RA, MacLean PD: Effects of vagal volleys on units of intralaminar and juxtalaminar thalamic nuclei in monkeys. Brain Res 1977, 130:271-286.
28. MacLean PD: The Triune Brain in Evolution: Role in Paleocerebral Functions. New York: Plenum Press; 1990.
29. Henry TR: Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002, 59(6 Suppl 4):S3-S14.
30. Naritoku DK, Terry WJ, Helfert RH: Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995, 22:53-62.
31. Chae JH, Nahas Z, Lomarev M, et al.: A review of functional neuroimaging studies of vagus nerve stimulation (VNS). J Psychiatr Res 2003, 37:443-455.
32. Ben-Menachem E, Hamberger A, Hedner T, et al.: Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epilepsy Res 1995, 20:221-227.
33. Carpenter LL, Moreno FA, Kling MA, et al.: Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biol Psychiatry 2004, 56:418-426.
34. Nagarajan L, Walsh P, Gregory P, Lee M: VNS therapy in clinical practice in children with refractory epilepsy. Acta Neurol Scand 2002, 105:13-17.
35. Schachter SC, Saper CB: Vagus nerve stimulation. Epilepsia 1998, 39:677-686.
36. Sackeim HA: The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001, 62(Suppl 16):10-17.
37. Rush AJ, George MS, Sackeim HA, et al.: Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000, 47:276-286.
38. Sackeim HA, Rush AJ, George MS, et al.: Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001, 25:713-728.
39. Marangell LB, Rush AJ, George MS, et al.: Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry 2002, 51:280-287.
40. Nahas Z, Marangell LB, Husain MM, et al.: Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005, 66:1097-1104.
41. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 12:56-62.
42. Rush AJ, Marangell LB, Sackeim HA, et al.: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005, 58:347-354.
43. Nahas Z, Bohning DE, Mu Q, et al.: Serial vagus nerve stimulation functional MRI (VNS/fMRI) in treatment-resistant depression. Biol Psychiatry 2003, 53(Suppl):212S.
44. Rush AJ, Sackeim HA, Marangell LB, et al.: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005, 58:355-363.
45. George MS, Rush AJ, Marangell LB, et al.: A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005, 58:364-373.
46. Corcoran CD, Thomas P, Phillips J, O'Keane V: Vagus nerve stimulation in chronic treatment-resistant depression: preliminary findings of an open-label study. Br J Psychiatry 2006, 189:282-283.
47. Koo B, Ham SD, Sood S, Tarver B: Human vagus nerve electrophysiology: a guide to vagus nerve stimulation parameters. J Clin Neurophysiol 2001, 18:429-433.
48. Sackeim HA, Rush AJ, Marangell LB, et al.: Long-term antidepressant effects of vagus nerve stimulation (VNS) in treatment-resistant depression. Poster presented at the 43rd Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico; December 12-16, 2004.
49. Prudic J, Olfson M, Marcus SC, et al.: Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry 2004, 55:301-312.
50. Burke MJ, Husain MM: Concomitant use of vagus nerve stimulation and electroconvulsive therapy for treatment-resistant depression. J Ect 2006, 22:218-222.
51. Lurie P, Stine N: Responding to three articles regarding vagus nerve stimulation (VNS) for depression. Biol Psychiatry 2006. [Epub ahead of print].
52. Rush AJ, George MS: Reply. Biol Psychiatry 2006. [Epub ahead of print].